Clinical outcomes in patients with diffuse large B cell lymphoma with a partial response to first-line R-CHOP chemotherapy: prognostic value of secondary International Prognostic Index scores and Deauville scores
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hyewon | - |
dc.contributor.author | Kim, Yu Ri | - |
dc.contributor.author | Kim, Soo-Jeong | - |
dc.contributor.author | Park, Yong | - |
dc.contributor.author | Eom, Hyeon-Seok | - |
dc.contributor.author | Oh, Sung Yong | - |
dc.contributor.author | Kim, Hyo Jung | - |
dc.contributor.author | Kang, Hye Jin | - |
dc.contributor.author | Lee, Won-Sik | - |
dc.contributor.author | Moon, Joon Ho | - |
dc.contributor.author | Won, Young-Woong | - |
dc.contributor.author | Kim, Tae-Sung | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.date.accessioned | 2021-09-02T23:53:11Z | - |
dc.date.available | 2021-09-02T23:53:11Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2017-11 | - |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/81788 | - |
dc.description.abstract | After introducing a rituximab-containing chemoimmunotherapy (R-CHOP) for diffuse large B cell lymphoma (DLBCL), a partial response (PR) which is regarded as treatment failure is still observed. To investigate the prognostic factors for the DLBCL patients with a PR to R-CHOP, we retrospectively evaluated 758 newly diagnosed DLBCL patients. After R-CHOP, 88 (11.6%) achieved a PR. Three-year progression-free and overall survival rates measured from the date of PR achievement (PFS2 and OS2) were 57.4 and 67.8%, respectively. The secondary International Prognostic Index (IPI2) scores after R-CHOP were low (0-1) in 68.2% and high (2-3) in 31.8% of the patients. The Deauville scores from 18-fluorodeoxyglucose positron emission tomography after R-CHOP showed low (2-3) in 58.0% and high (4) in 42.0% of the patients. High IPI2 and high Deauville scores were associated with worse PFS2 (P < 0.001 and P = 0.009) and OS2 (P = 0.013 and P = 0.067). The high-risk group defined by the IPI2 and Deauville scores, whose scores were both high, showed significantly lower 3-year PFS2 (P < 0.001) and OS2 (P = 0.006) rates compared with those of the other groups. In multivariate analyses, the IPI score of >= 3 at diagnosis and bone marrow involvement at diagnosis were independent prognostic factors. In addition, high IPI2-Deauville score after R-CHOP was significantly associated with poor PFS2 (P = 0.009) and demonstrated a trend toward inferior OS2. In conclusion, DLBCL patients who partially responded to R-CHOP are still a heterogeneous group, for which IPI2 and Deauville scores should be evaluated for prediction of prognosis. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | BONE-MARROW-TRANSPLANTATION | - |
dc.subject | NON-HODGKIN-LYMPHOMA | - |
dc.subject | AUTOLOGOUS TRANSPLANTATION | - |
dc.subject | ELDERLY-PATIENTS | - |
dc.subject | PLUS RITUXIMAB | - |
dc.subject | DES-LYMPHOMES | - |
dc.subject | CRITERIA | - |
dc.subject | WORKSHOP | - |
dc.subject | TRIAL | - |
dc.title | Clinical outcomes in patients with diffuse large B cell lymphoma with a partial response to first-line R-CHOP chemotherapy: prognostic value of secondary International Prognostic Index scores and Deauville scores | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Yong | - |
dc.identifier.doi | 10.1007/s00277-017-3107-6 | - |
dc.identifier.scopusid | 2-s2.0-85027848688 | - |
dc.identifier.wosid | 000413247400011 | - |
dc.identifier.bibliographicCitation | ANNALS OF HEMATOLOGY, v.96, no.11, pp.1873 - 1881 | - |
dc.relation.isPartOf | ANNALS OF HEMATOLOGY | - |
dc.citation.title | ANNALS OF HEMATOLOGY | - |
dc.citation.volume | 96 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 1873 | - |
dc.citation.endPage | 1881 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordPlus | BONE-MARROW-TRANSPLANTATION | - |
dc.subject.keywordPlus | NON-HODGKIN-LYMPHOMA | - |
dc.subject.keywordPlus | AUTOLOGOUS TRANSPLANTATION | - |
dc.subject.keywordPlus | ELDERLY-PATIENTS | - |
dc.subject.keywordPlus | PLUS RITUXIMAB | - |
dc.subject.keywordPlus | DES-LYMPHOMES | - |
dc.subject.keywordPlus | CRITERIA | - |
dc.subject.keywordPlus | WORKSHOP | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordAuthor | Diffuse large B cell lymphoma | - |
dc.subject.keywordAuthor | Partial response | - |
dc.subject.keywordAuthor | International Prognostic Index | - |
dc.subject.keywordAuthor | FDG-PET | - |
dc.subject.keywordAuthor | Deauville scores | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.